Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) announced a new computational analysis method called Tandem Repeat Genotyping Tool (TRGT) for studying tandem repeats (TRs) in the human genome. This tool enables comprehensive profiling of TRs and their methylation status, aiding researchers in understanding their role in diseases like ALS and Fragile X syndrome. TRGT improves the analysis of genetic variations and can identify disease-causing TRs. The tool is available on GitHub alongside a companion visualization tool, enhancing usability for genomic research.
PacBio (NASDAQ: PACB) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 14 at 1:30 p.m. Eastern Time. A fireside chat with management will be accessible via a live webcast on the company's investor page. The event will conclude with a replay available for 30 days. PacBio is known for its advanced sequencing solutions, addressing complex genetic research across various applications, including oncology and infectious diseases. For more details, visit www.pacb.com.
PacBio (NASDAQ: PACB) announced the grant of non-qualified stock options covering 475,000 shares to its new Chief Commercial Officer, Jeff Eidel, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan, effective August 16, 2022. The options have an exercise price of $8.00, which matches the closing stock price on the effective date. The vesting schedule includes 1/4 of the shares vesting after one year, followed by monthly vesting of 1/48 thereafter, contingent on Eidel’s continued service.
PacBio (NASDAQ: PACB) announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California, on August 11, 2022. The company will host a fireside chat at 11:00 a.m. Pacific Time, which will be available via live webcast on their investors page. A replay will be accessible for 30 days post-event. PacBio specializes in advanced sequencing solutions, focusing on accuracy and quality across diverse applications, including oncology and infectious diseases. For more information, visit www.pacb.com.
PacBio (NASDAQ: PACB) reported a second-quarter revenue of $35.5 million, marking a 16% increase year-over-year. Instrument revenue reached $15.6 million, while consumables generated $14.6 million. Gross profit rose to $16.2 million with a gross margin of 46%. However, operating expenses surged to $84.2 million, reflecting higher costs, leading to a net loss of $71.4 million. The company anticipates 2022 revenue between $138 million and $145 million due to macroeconomic challenges, including supply chain issues and inflation.
PacBio (NASDAQ: PACB) has appointed Jeff Eidel as Chief Commercial Officer, effective August 16, 2022. Eidel will oversee all global commercial activities, including sales and marketing. He previously served as CEO of Cradle Genomics and held senior roles at Illumina, where he contributed to significant business growth and product launches. CEO Christian Henry expressed optimism about Eidel's potential to enhance PacBio's commercial strategy as the company aims to expand its sequencing portfolio and work towards profitability.
PacBio (NASDAQ: PACB) will hold its quarterly conference call on August 3, 2022, at 5:00 pm ET to discuss its Q2 2022 financial results. The call will be accessible via webcast on the company's investor relations website. Interested participants can listen online or dial in using toll-free or international numbers. PacBio specializes in advanced sequencing solutions for scientific and clinical research, focusing on accuracy and quality through its HiFi long read and SBB® short read sequencing technologies.
PacBio (NASDAQ: PACB) recently announced the granting of non-qualified stock options for 100,000 shares and restricted stock units (RSUs) for 50,000 shares to a newly hired employee. This issuance is part of the 2020 Inducement Equity Incentive Plan, effective June 21, 2022. The options have an exercise price of $4.61, matching the stock's closing price on the effective date. The vesting schedule for the options and RSUs spans four years with a combination of annual and monthly vesting milestones.
PacBio will present at the BofA Securities 2022 Healthcare Conference on May 12 at 11:20 a.m. PT. The presentation will be available via live webcast on their investors page, with a replay for 30 days post-event. The conference takes place in Las Vegas, Nevada.
PacBio, traded under the symbol PACB, focuses on advanced sequencing technologies to aid scientists in addressing complex genetic issues. Their offerings include HiFi long read and SBB short read sequencing, applicable in various research areas such as oncology and infectious diseases.
PacBio (NASDAQ: PACB) reported a 14% increase in revenue for the first quarter of 2022, totaling $33.2 million, compared to $29.0 million in Q1 2021. The company delivered a record 50 Sequel II/IIe systems, increasing their installed base to 424 systems. Gross profit rose 9% to $14.2 million, with a gross margin of 43%. However, operating expenses surged to $91.7 million, leading to a net loss of $81.5 million, a slight improvement from a net loss of $87.4 million in the previous year.